Emerging Treatment Options for Unmet Need in Complement 3 Glomerulopathy

Balancing Relative Risk of Poor Functional Outcomes Guides Factor Xa Inhibitor Reversal Agent Selection

Expanding Options for Hereditary Transthyretin Amyloidosis with Polyneuropathy

Reversal Agent for Factor Xa Inhibitors Mitigates Intracranial Bleeding in Phase 4 Trial

Long-term Efficacy in CLL: Expanding Evidence Across Treatment-naïve and Relapsed/Refractory Patients

BTK Inhibitors Differentiated on Safety and Efficacy in CLL

Conditioning for Allogeneic Hematopoietic Stem Cell: Strategies Compared

Opportunities to Improve Survival in Heart Failure in Canada

ALPINE Head-to-head Trial, Second-generation BTK Inhibitor Shown to be More Effective and Safer in CLL

Lipid-lowering Efficacy Sustained Over 4 Years with Twice-yearly Injections of a First-in-class Therapy

Gene Replacement Therapy Fosters Age-appropriate Development in Spinal Muscular Atrophy

Phase 3 Trials Promise Highly Effective Option for Hidradenitis Suppurativa